Navigation Links
Immucor Settles SEC Investigation
Date:9/28/2007

Court Approves Class Action Settlement

NORCROSS, Ga., Sept. 28 /PRNewswire-FirstCall/ -- Immucor, Inc. (Nasdaq: BLUD), the global leader in providing automated instrument-reagent systems to the blood transfusion industry, announced today that the Securities and Exchange Commission (SEC) has agreed to a complete settlement of its previously-disclosed investigation into certain activities involving the company's Italian subsidiary.

Under the settlement, without admitting or denying any wrongdoing, the company consented to the entry of an order that it cease and desist from future violations of Sections 13(b)(2)(A), 13(b)(2)(B) and 30A of the Securities Exchange Act of 1934. The SEC did not impose any monetary penalty against the company or require the company to take any further action.

The SEC also approved a separate settlement with Dr. Gioacchino De Chirico, the company's President and CEO, related to the same investigation. Without admitting or denying any wrongdoing, Dr. De Chirico agreed to pay a $30,000 civil penalty and consented to the entry of an order that he cease and desist from causing future violations of Sections 13(b)(2)(A) and 13(b)(2)(B) of the Securities Exchange Act of 1934.

In an unrelated development, on September 26, 2007, the United States District Court for the Northern District of Georgia granted final approval of the settlement of the previously-disclosed class action lawsuit entitled In re Immucor, Inc. Securities Litigation, filed in 2005. Under the settlement, which was previously reported, the company's insurance carrier agreed to pay $2.5 million to the plaintiff class in consideration of an unconditional release of all claims against the company and the individual defendants. The company's only costs were certain legal defense expenses, which have been expensed as incurred. The Court's approval concludes the company's involvement in this litigation and terminates the claims asserted in this litigation as to all class members.

Founded in 1982, Immucor manufactures and sells a complete line of reagents and systems used by hospitals, reference laboratories and donor centers to detect and identify certain properties of the cell and serum components of blood prior to transfusion. Immucor markets a complete family of automated instrumentation for all of its market segments. For more information on Immucor, please visit our website at http://www.immucor.com.


'/>"/>
SOURCE Immucor, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Cytochroma settles lawsuit with Genzyme
2. WARF settles patent dispute with IBM
3. Merge execs step down following investigation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... BioMedGPS announces ... addition of its newest module, US Hemostats & Sealants. , SmartTRAK’s US Market ... hemostats, fibrin sealants, synthetic sealants and biologic sealants used in surgical applications. BioMedGPS ...
(Date:10/11/2017)... N.C. (PRWEB) , ... October 11, 2017 , ... ... ARCS® Foundation President Andi Purple announced Dr. Suneel I. Sheikh, the co-founder, ... ( ASTER Labs ), Inc. has been selected for membership in ARCS ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ComplianceOnline’s Medical Device ... on 7th and 8th June 2018 in San Francisco, CA. The Summit brings together ... as several distinguished CEOs, board directors and government officials from around the world to ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017  SkylineDx ... London (ICR) and University of Leeds ... to risk-stratify patients with multiple myeloma (MM), in a multi-centric ... The University of Leeds is the ... UK, and ICR will perform the testing services to include ...
Breaking Biology Technology:
(Date:3/28/2017)... PUNE, India , March 28, 2017 ... (Analog, IP, Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), ... Maintenance), Vertical, and Region - Global Forecast to 2022", ... 30.37 Billion in 2016 and is projected to reach ... 15.4% between 2017 and 2022. The base year considered ...
(Date:3/24/2017)... The Controller General of Immigration from Maldives Mr. ... have received the prestigious international IAIR Award for the most innovative ... ... Maldives Immigration ... Algeen (small picture on the right) have received the IAIR award for ...
(Date:3/23/2017)... -- The report "Gesture Recognition and Touchless Sensing Market by Technology ... Forecast to 2022", published by MarketsandMarkets, the market is expected to be worth ... and 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):